PATHOQUEST
23.1.2020 14:02:09 CET | Business Wire | Press release
PathoQuest, a company with expertise in genomic analysis, announced today that it has received GLP certificate of conformity following a successful inspection by the French National Agency for Medicine and Health Products Safety (ANSM). PathoQuest is the first company in France to have a facility receive such a GLP certificate from the ANSM for advanced, Next Generation Sequencing viral safety testing (“high-throughput sequencing detection of incidental replicative virus test in eukaryote cells ”).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200123005345/en/
Violaine Melen, PathoQuest’s Chief of Quality Assurance and Regulatory Affairs, stated “we are really proud of the achievement of this key regulatory milestone. Receiving this GLP certificate is the confirmation of the quality of our entire process, from receipt of a biological sample to report generation, inclusive of bioinformatics analysis and data archiving. Our processes have been validated in accordance with highly recognized validation methods and computer systems guidelines such as ICHQ2(R1), IEC 62304, 21 CRF part 11, OECD annex 17.”
Next generation sequencing-based technology for biologics testing is intended to supplement or replace traditional in-vivo or in-vitro testing methods in order to support more rapid and robust decision-making as a part of the QC process. Jean-François Brepson, PathoQuest’s CEO, commented “Thanks to efficient teamwork, PathoQuest is now able to offer GLP-certified viral safety testing based on our proprietary NGS approach. This certification provides the company with a significant new market opportunity in addition to the current testing we perform in a R&D environment. Our innovative QC process is particularly adapted to biotech and biopharma companies developing Advanced Therapy Medicinal Products (ATMPs), vaccines and other biologicals .”
About PathoQuest
PathoQuest offers biopharmaceutical companies a game changing Genomic approach to secure the biosafety of biological drugs like cell & gene therapy products, vaccines and recombinant. It allows to reduce time to market of innovative treatments.
PathoQuest’s technology combines a Next-Generation Sequencing (NGS) platform with a proprietary sample preparation processes completed by a proprietary pathogen genome sequence databases and automated analysis pipeline.
PathoQuest has signed in 2018 a strategic partnership with Charles River Lab (Boston, USA).
Based on its technological platform, PathoQuest has also developed a metagenomic test direct from blood (iDTECT®) to improve the diagnosis of Bloodstream infections and fight against Antimicrobial Resistance (AMR)
For more information about PathoQuest, visit www.pathoquest.com or contact us at welcome@pathoquest.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200123005345/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hephaestus Exits Stealth Having Raised $17.2M to Supply Rare-Earth-Free HTS Superconductors and Build Low-Cost Fusion Power21.10.2026 16:48:00 CEST | Press release
CiRi Ventures leads latest funding round as novel HTS magnets head to manufacturing in 2027, ahead of a negative triangularity reactor targeting net energy gain by 2030 Hephaestus today emerged from stealth with solutions that address two of the largest cost drivers in fusion power: the high temperature superconducting (HTS) magnets that confine the plasma, and the edge-localized modes (ELMs – major plasma instabilities) that drive up the cost and complexity of conventional reactor designs. The company also announced the close of a new funding round led by CiRi Ventures. Hephaestus was founded in London in 2019 with a single mission – to help make fusion energy cheap enough to compete on the grid. Its AI plasma solver initially swept the full space of tokamak design parameters, unconstrained by the legacy designs and materials much of the industry is already committed to, and identified negative triangularity (NT), which inverts the D-shaped plasma used in most tokamaks, as the most li
New TOURISE and LIONS Advisory Study Reveals How Creativity Creates a Commercial Advantage for Destination Growth21.10.2026 16:27:00 CEST | Press release
50% of travelers cannot remember the last advertisement they saw for a tourism company or destination, with a further 7% unsureTourism faces an $11 billion marketing investment gap: restoring the category’s share of voice to 3% would require global travel and transport ad spend to reach $43.4 billion by 202763% of Large Language Model (LLM) visibility is driven by long-term brand equity, compared with 22% from current marketing activity and 11% from citation volume TOURISE, the world’s premier platform for shaping the future of global tourism, today released IDEAS That Travel, a new report developed in collaboration with LIONS Advisory. The study finds that while travel demand is rising, tourism brands are competing for attention in a more fragmented, socially driven and AI-mediated environment, where visibility alone is no longer enough to secure preference and growth. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026102116
DEWA International Signs 4 MoUs With Global Partners During WETEX 202621.10.2026 16:12:00 CEST | Press release
DEWA International signed four memorandums of understanding (MoUs) with leading global entities during the Water, Energy, Technology and Environment Exhibition (WETEX 2026). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261021351329/en/ DEWA International signs 4 MoUs with global partners during WETEX 2026 (Photo: AETOSWire) HE Saeed Mohammed Al Tayer, MD&CEO of Dubai Electricity and Water Authority (DEWA) and Chairman of DEWA International, said: “We are committed to building strategic partnerships with leading international institutions that possess extensive expertise in developing and implementing energy, water and infrastructure projects, while exploring future collaboration opportunities across key sectors. Through these MoUs, we aim to exchange knowledge and expertise and leverage best practices and advanced technologies. These efforts will help accelerate the transition to clean energy, enhance the resilience and ef
Picsart Launches Marketing Studio to Help Businesses Create, Test and Run Google Ads21.10.2026 16:03:00 CEST | Press release
Key Takeaways: Picsart’s new Marketing Studio brings content creation, advertising strategy, creative testing and paid distribution into one guided space. Businesses can test concepts and videos using Zappi’s consumer insights and predictive technology, then create and launch Google Ads campaigns directly within Picsart. Built primarily for small-business owners, solopreneurs and performance marketeers, Marketing Studio connects creative work with advertising performance, helping businesses use campaign results to guide what they make next. Picsart, the AI media production and distribution platform, where 100M+ creators and businesses worldwide make, market and monetize content, today launched Marketing Studio, bringing content creation, advertising strategy, creative testing and paid distribution into one connected experience. Available now, Marketing Studio combines market insights from Zappi with a Google Ads integration that lets businesses create and launch campaigns directly with
Interactive Brokers Introduces Autonomous Trading21.10.2026 16:00:00 CEST | Press release
Eligible clients can authorize connected AI to monitor 75,000+ listed stocks, options and ETFs worldwide and submit supported trades on their behalf based on criteria they define Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced IBKR Autonomous Trading, a new capability that allows eligible clients to authorize connected AI platforms to identify trading opportunities across more than 75,000 listed stocks, options and ETFs worldwide and submit supported orders within a dedicated AI Partition. Clients can create and fund their AI Partition by transferring funds from their main IBKR account, without opening a new account or making an external deposit. The AI operates based on client-defined instructions, subject to account restrictions and safeguards designed to help manage risk. Through natural language, clients can access Interactive Brokers' extensive trading capabilities and define how they want the AI to trade on their behalf. “For decades, Interactive B
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom